Business

FDA Panelist Confirms Conflict of Interest

A doctor did not disclose a conflict of interest before participating in an influential FDA panel looking into a new muscular dystrophy drug

Published March 31, 2015 • Updated on March 31, 2015 at 4:27 pm

A doctor did not disclose a conflict of interest before participating in an influential FDA panel looking into a new muscular dystrophy drug, the Boston Business Journal reports.

BBJ BioFlash Editor Don Seiffert joined necn to discuss, saying that Sarepta Therapeutics is among the companies potentially impacted.

Read the full BBJ article here.

Business

FDA Panelist Confirms Conflict of Interest

A doctor did not disclose a conflict of interest before participating in an influential FDA panel looking into a new muscular dystrophy drug

Published March 31, 2015 • Updated on March 31, 2015 at 4:27 pm

Follow Us